Results 21 to 30 of about 2,347,326 (232)
Aggressive B-cell lymphomas (ABLs) are a group of B-cell malignancies, that is, a relatively common form of cancer across the world. This issue on aggressive B-cell lymphomas compiles 12 exciting manuscripts, most of which are very meticulously performed reviews of the available current literature.
Naresh KN +3 more
openaire +4 more sources
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel
S. Schuster +23 more
semanticscholar +1 more source
Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke +2 more
core +1 more source
Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study
Background: Extranodal non-Hodgkin lymphoma (NHL) is more prevalent in the gastrointestinal (GI) tract than in other sites. This study aimed to determine the endoscopic characteristics of primary gastrointestinal non-Hodgkin lymphomas.
Quang Trung Tran +7 more
doaj +1 more source
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
BACKGROUND Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy.
Michael R. Bishop +40 more
semanticscholar +1 more source
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. [PDF]
Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of ...
Aliberti S +24 more
core +1 more source
Primary mediastinal lymphoma: diagnosis and treatment options. [PDF]
Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a
DI ROCCO, Alice +4 more
core +1 more source
Background Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned.Design and Methods We studied the gene expression profile of 43 follicular lymphomas, 50 B-cell non-Hodgkin’s lymphomas of
Pier Paolo Piccaluga +11 more
doaj +1 more source
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Brennan, Cameron W. +41 more
core +2 more sources
Background Multiparameter flow cytometry allows the detection of minor monoclonal B-cell populations. Using this technique combined with morphology, we were struck by the presence of minor populations of small monoclonal B cells in bone marrows of ...
Anne M. Tierens +6 more
doaj +1 more source

